Literature DB >> 18239598

Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet.

Katarzyna M Starowicz1, Luigia Cristino, Isabel Matias, Raffaele Capasso, Alessandro Racioppi, Angelo A Izzo, Vincenzo Di Marzo.   

Abstract

OBJECTIVE: In mice, endocannabinoids (ECs) modulate insulin release from pancreatic beta-cells and adipokine expression in adipocytes through cannabinoid receptors. Their pancreatic and adipose tissue levels are elevated during hyperglycemia and obesity, but the mechanisms underlying these alterations are not understood. METHODS AND PROCEDURES: We assessed in mice fed for up to 14 weeks with a standard or high-fat diet (HFD): (i) the expression of cannabinoid receptors and EC biosynthesizing enzymes (N-acyl-phosphatidyl-ethanolamine-selective phospholipase D (NAPE-PLD) and DAGLalpha) and degrading enzymes (fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) in pancreatic and adipose tissue sections by immunohistochemical staining; (ii) the amounts, measured by liquid chromatography-mass spectrometry, of the ECs, 2-AG, and anandamide (AEA).
RESULTS: Although CB(1) receptors and biosynthetic enzymes were found mostly in alpha-cells, degrading enzymes were identified in beta-cells. Following HFD, staining for biosynthetic enzymes in beta-cells and lower staining for FAAH were observed together with an increase of EC pancreatic levels. While we observed no diet-induced change in the intensity of the staining of EC metabolic enzymes in the mesenteric visceral fat, a decrease in EC concentrations was accompanied by lower and higher staining of biosynthesizing enzymes and FAAH, respectively, in the subcutaneous fat. No change in cannabinoid receptor staining was observed following HFD in any of the analyzed tissues. DISCUSSION: We provide unprecedented information on the distribution of EC metabolic enzymes in the pancreas and adipose organ, where their aberrant expression during hyperglycemia and obesity contribute to dysregulated EC levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239598     DOI: 10.1038/oby.2007.106

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  77 in total

1.  Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.

Authors:  Christopher J Lynch; Qing Zhou; Show-Ling Shyng; David J Heal; Sharon C Cheetham; Keith Dickinson; Peter Gregory; Michael Firnges; Ulrich Nordheim; Stephanie Goshorn; Dania Reiche; Lechoslaw Turski; Jochen Antel
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

2.  Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.

Authors:  Mónica Alonso; Antonia Serrano; Margarita Vida; Ana Crespillo; Laura Hernandez-Folgado; Nadine Jagerovic; Pilar Goya; Carmen Reyes-Cabello; Vidal Perez-Valero; Juan Decara; Manuel Macías-González; Francisco Javier Bermúdez-Silva; Juan Suárez; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.

Authors:  Isabel González-Mariscal; Susan M Krzysik-Walker; Wook Kim; Michael Rouse; Josephine M Egan
Journal:  Mol Cell Endocrinol       Date:  2015-12-25       Impact factor: 4.102

4.  A TRPV1-to-secretagogin regulatory axis controls pancreatic β-cell survival by modulating protein turnover.

Authors:  Katarzyna Malenczyk; Fatima Girach; Edit Szodorai; Petter Storm; Åsa Segerstolpe; Giuseppe Tortoriello; Robert Schnell; Jan Mulder; Roman A Romanov; Erzsébet Borók; Fabiana Piscitelli; Vincenzo Di Marzo; Gábor Szabó; Rickard Sandberg; Stefan Kubicek; Gert Lubec; Tomas Hökfelt; Ludwig Wagner; Leif Groop; Tibor Harkany
Journal:  EMBO J       Date:  2017-06-21       Impact factor: 11.598

Review 5.  Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle.

Authors:  Cristoforo Silvestri; Alessia Ligresti; Vincenzo Di Marzo
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

6.  Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.

Authors:  Shiran Udi; Liad Hinden; Brian Earley; Adi Drori; Noa Reuveni; Rivka Hadar; Resat Cinar; Alina Nemirovski; Joseph Tam
Journal:  J Am Soc Nephrol       Date:  2017-08-31       Impact factor: 10.121

Review 7.  The dysregulation of the endocannabinoid system in diabesity-a tricky problem.

Authors:  Thomas Scherer; Christoph Buettner
Journal:  J Mol Med (Berl)       Date:  2009-03-17       Impact factor: 4.599

Review 8.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

9.  N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

Authors:  Zhi-Liang Chu; Chris Carroll; Ruoping Chen; Jean Alfonso; Veronica Gutierrez; Hongmei He; Annette Lucman; Charles Xing; Kristen Sebring; Jinyao Zhou; Brandee Wagner; David Unett; Robert M Jones; Dominic P Behan; James Leonard
Journal:  Mol Endocrinol       Date:  2009-11-09

10.  Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis.

Authors:  Vanessa Deveaux; Thomas Cadoudal; Yasukatsu Ichigotani; Fatima Teixeira-Clerc; Alexandre Louvet; Sylvie Manin; Jeanne Tran-Van Nhieu; Marie Pierre Belot; Andreas Zimmer; Patrick Even; Patrice D Cani; Claude Knauf; Remy Burcelin; Adeline Bertola; Yannick Le Marchand-Brustel; Philippe Gual; Ariane Mallat; Sophie Lotersztajn
Journal:  PLoS One       Date:  2009-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.